Safety terms keep risk, population, product, and co-exposure context visible.
Dictionary / Safety
Adverse event
A safety observation reported in a source, with context about population and product.
Safetyterm category
8related public pages
editorial navigationdefinition status
draftreview status
369exact evidence rows
323exact source links
411nearby evidence rows
304nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Adverse event explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
323 direct sources linked to approved workbench claims. PubMed 37796540
411 nearby evidence rows and 304 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Adverse event is used in this encyclopedia as a safety term. A safety observation reported in a source, with context about population and product.
Safety terms should stay close to population, dose, product, route, medicine-use, and adverse-event context. They should be read as risk-mapping language, not personal medical guidance.
Also searched as: adverse events, side effect, side effects, tolerability.
Evidence Guardrail
How to read it without overreaching
Safety pages are heightened-context pages. Population, dose, route, co-medications, pregnancy, pediatrics, impairment, and adverse-event details matter before any evidence is generalized.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 37796540
Distinct source records under those exact rows. PubMed 37796540
Source-backed public pages where this vocabulary is likely useful. Open related page
Evidence rows available on those related public pages. Open related page
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 37796540
- Open related pages.Use nearby pages for broader source-backed context. Related page
- Keep the boundary.Safety vocabulary is not personal medical advice; population and co-medication context matter.
Exact Evidence Rows
Approved source-backed rows linked to this term
369 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
44 exact rows / 30 sources
Evidence row 2 / safety context
CBN decreases Nighttime awakenings.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 3 / safety context
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 4 / safety context
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 5 / safety context
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 14 / safety context
CBN decreases Overall sleep disturbance.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 15 / safety context
CBN associated with Adverse events.
preliminary human / low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 16 / safety context
CBN no detected effect on Sleep onset latency.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 17 / safety context
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 18 / safety context
CBN no detected effect on Daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 28 / safety context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PubMed 38797087
Claim or source metadata contains an explicit term marker.
Evidence row 29 / safety context
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PubMed 35617670
Claim or source metadata contains an explicit term marker.
Evidence row 46 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preliminary human / very_low confidence.
Cannabinoid Content in Cannabis Flowers and Homemade Cannabis-Based Products Used for Therapeutic Purposes in Argentina. PubMed 33998894
Claim or source metadata contains an explicit term marker.
Evidence row 86 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preliminary human / very_low confidence.
Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows. PubMed 37641272
Claim or source metadata contains an explicit term marker.
Evidence row 97 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse events associated with medical cannabis reported within a centralized call center. PubMed 42158949
Claim or source metadata contains an explicit term marker.
Evidence row 149 / safety context
CBN studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 155 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. PubMed 36941718
Claim or source metadata contains an explicit term marker.
Evidence row 156 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. PubMed 38696245
Claim or source metadata contains an explicit term marker.
Evidence row 159 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 162 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Claim or source metadata contains an explicit term marker.
Evidence row 163 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Claim or source metadata contains an explicit term marker.
Evidence row 169 / safety context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 221 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
The contribution of addictovigilance data to the French medical cannabis experimentation. PubMed 39547825
Claim or source metadata contains an explicit term marker.
Evidence row 227 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PubMed 42204954
Claim or source metadata contains an explicit term marker.
Evidence row 238 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse Effects of Recreational and Medical Cannabis. PubMed 33897066
Claim or source metadata contains an explicit term marker.
Evidence row 321 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PubMed 26724101
Claim or source metadata contains an explicit term marker.
Evidence row 323 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PubMed 29768152
Claim or source metadata contains an explicit term marker.
Evidence row 324 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PubMed 28538134
Claim or source metadata contains an explicit term marker.
Evidence row 334 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Potency Analysis of Medical Marijuana Products from New York State. PubMed 31559335
Claim or source metadata contains an explicit term marker.
Evidence row 338 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinoids in dermatology: a scoping review. PubMed 30142706
Claim or source metadata contains an explicit term marker.
Evidence row 350 / safety context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. PubMed 38127427
Claim or source metadata contains an explicit term marker.
Evidence row 351 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Derivation of a health-based guidance value for Δ8-tetrahydrocannabinol (Δ8-THC) and its occurrence in food. PubMed 41262681
Claim or source metadata contains an explicit term marker.
Evidence row 354 / safety context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
[Not Available]. PubMed 39323250
Claim or source metadata contains an explicit term marker.
Evidence row 508 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 509 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 510 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Claim or source metadata contains an explicit term marker.
Evidence row 512 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 544 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 546 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Claim or source metadata contains an explicit term marker.
Evidence row 637 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Claim or source metadata contains an explicit term marker.
Evidence row 641 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 745 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Claim or source metadata contains an explicit term marker.
Evidence row 1173 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. PubMed 29778785
Claim or source metadata contains an explicit term marker.
Evidence row 1175 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder. PubMed 37298321
Claim or source metadata contains an explicit term marker.
Evidence row 1192 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: results from the Pain in Neuropathy Study. PubMed 37578507
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
200 exact rows / 178 sources
Evidence row 22 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Claim or source metadata contains an explicit term marker.
Evidence row 23 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Cannabidiol's impact on drug-metabolization. PubMed 37541924
Claim or source metadata contains an explicit term marker.
Evidence row 24 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. PubMed 35156171
Claim or source metadata contains an explicit term marker.
Evidence row 25 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. PubMed 33497784
Claim or source metadata contains an explicit term marker.
Evidence row 26 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Cannabis and driving ability. PubMed 33839427
Claim or source metadata contains an explicit term marker.
Evidence row 27 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. PubMed 40172477
Claim or source metadata contains an explicit term marker.
Evidence row 45 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Claim or source metadata contains an explicit term marker.
Evidence row 48 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Memantine for autism spectrum disorder. PubMed 36006807
Claim or source metadata contains an explicit term marker.
Evidence row 49 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. PubMed 39007525
Claim or source metadata contains an explicit term marker.
Evidence row 50 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. PubMed 39854828
Claim or source metadata contains an explicit term marker.
Evidence row 51 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. PubMed 31288397
Claim or source metadata contains an explicit term marker.
Evidence row 52 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
insufficient / very_low confidence.
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. PubMed 32918835
Claim or source metadata contains an explicit term marker.
Evidence row 53 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Claim or source metadata contains an explicit term marker.
Evidence row 54 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Mechanisms of cannabis impairment: Implications for modeling driving performance. PubMed 34634690
Claim or source metadata contains an explicit term marker.
Evidence row 55 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Prescribing medicinal cannabis. PubMed 33093741
Claim or source metadata contains an explicit term marker.
Evidence row 56 / safety context
THC associated with driving impairment or safety-relevant performance outcomes.
insufficient / very_low confidence.
Driving Impairment Cases Involving Etizolam and Flubromazolam. PubMed 32399568
Claim or source metadata contains an explicit term marker.
Evidence row 84 / safety context
CBDV studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. PubMed 42339654
Claim or source metadata contains an explicit term marker.
Evidence row 87 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag(I) Retention Zone and Chromogenic Smartphone Detection. PubMed 36178203
Claim or source metadata contains an explicit term marker.
Evidence row 90 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. PubMed 37810707
Claim or source metadata contains an explicit term marker.
Evidence row 91 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PubMed 38862388
Claim or source metadata contains an explicit term marker.
Evidence row 92 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
insufficient / very_low confidence.
Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. PubMed 28117322
Claim or source metadata contains an explicit term marker.
Evidence row 93 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacologic treatment of fibromyalgia: an update. PubMed 41142233
Claim or source metadata contains an explicit term marker.
Evidence row 94 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. PubMed 21845389
Claim or source metadata contains an explicit term marker.
Evidence row 95 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis-based medicines for chronic neuropathic pain in adults. PubMed 41548880
Claim or source metadata contains an explicit term marker.
Evidence row 96 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. PubMed 40708053
Claim or source metadata contains an explicit term marker.
Evidence row 150 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. PubMed 37217977
Claim or source metadata contains an explicit term marker.
Evidence row 151 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. PubMed 38868665
Claim or source metadata contains an explicit term marker.
Evidence row 152 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. PubMed 39805119
Claim or source metadata contains an explicit term marker.
Evidence row 153 / safety context
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. PubMed 38176407
Claim or source metadata contains an explicit term marker.
Evidence row 154 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Claim or source metadata contains an explicit term marker.
Evidence row 158 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Claim or source metadata contains an explicit term marker.
Evidence row 160 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Claim or source metadata contains an explicit term marker.
Evidence row 166 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Claim or source metadata contains an explicit term marker.
Evidence row 167 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 168 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 170 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Claim or source metadata contains an explicit term marker.
Evidence row 173 / safety context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Claim or source metadata contains an explicit term marker.
Evidence row 175 / safety context
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Claim or source metadata contains an explicit term marker.
Evidence row 196 / safety context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 197 / safety context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Update on Cannabidiol in Drug-Resistant Epilepsy. PubMed 39585547
Claim or source metadata contains an explicit term marker.
Evidence row 198 / safety context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. PubMed 31802404
Claim or source metadata contains an explicit term marker.
Evidence row 199 / safety context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. PubMed 33667843
Claim or source metadata contains an explicit term marker.
Evidence row 200 / safety context
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. PubMed 37593907
Claim or source metadata contains an explicit term marker.
Evidence row 217 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 218 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Use and the Risk for Psychosis and Affective Disorders. PubMed 31647377
Claim or source metadata contains an explicit term marker.
Evidence row 219 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PubMed 42309106
Claim or source metadata contains an explicit term marker.
Evidence row 220 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and psychiatric disorders. PubMed 20562767
Claim or source metadata contains an explicit term marker.
Evidence row 222 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Role of cannabis in cardiovascular disorders. PubMed 28840009
Claim or source metadata contains an explicit term marker.
Evidence row 228 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Claim or source metadata contains an explicit term marker.
Evidence row 229 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Clinical management of cannabis withdrawal. PubMed 34791767
Claim or source metadata contains an explicit term marker.
Evidence row 230 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PubMed 35510826
Claim or source metadata contains an explicit term marker.
Evidence row 231 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The differential effects of medicinal cannabis on mental health: A systematic review. PubMed 40186931
Claim or source metadata contains an explicit term marker.
Evidence row 232 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. PubMed 38562466
Claim or source metadata contains an explicit term marker.
Evidence row 237 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and monoaminergic system: implications for learning and memory. PubMed 39206116
Claim or source metadata contains an explicit term marker.
Evidence row 239 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prenatal cannabinoid exposure and altered neurotransmission. PubMed 30771373
Claim or source metadata contains an explicit term marker.
Evidence row 240 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. PubMed 26858214
Claim or source metadata contains an explicit term marker.
Evidence row 241 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid signaling and long-term synaptic plasticity. PubMed 19575681
Claim or source metadata contains an explicit term marker.
Evidence row 242 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. PubMed 42076122
Claim or source metadata contains an explicit term marker.
Evidence row 244 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
[Not all drugs are the same]. PubMed 23974649
Claim or source metadata contains an explicit term marker.
Evidence row 245 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. PubMed 41324909
Claim or source metadata contains an explicit term marker.
Evidence row 315 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PubMed 17005273
Claim or source metadata contains an explicit term marker.
Evidence row 316 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cardiovascular consequences of marijuana use. PubMed 12412838
Claim or source metadata contains an explicit term marker.
Evidence row 317 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PubMed 39575727
Claim or source metadata contains an explicit term marker.
Evidence row 318 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis use and acute coronary syndrome. PubMed 30964363
Claim or source metadata contains an explicit term marker.
Evidence row 319 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoids, blood pressure and the human heart. PubMed 18426501
Claim or source metadata contains an explicit term marker.
Evidence row 320 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 325 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PubMed 38940871
Claim or source metadata contains an explicit term marker.
Evidence row 326 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Statewide Variation in Cannabinoid Regulations. PubMed 36848540
Claim or source metadata contains an explicit term marker.
Evidence row 327 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. PubMed 33013414
Claim or source metadata contains an explicit term marker.
Evidence row 328 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. PubMed 31471034
Claim or source metadata contains an explicit term marker.
Evidence row 329 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. PubMed 32144889
Claim or source metadata contains an explicit term marker.
Evidence row 330 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. PubMed 27683558
Claim or source metadata contains an explicit term marker.
Evidence row 331 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. PubMed 35987236
Claim or source metadata contains an explicit term marker.
Evidence row 332 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. PubMed 40454463
Claim or source metadata contains an explicit term marker.
Evidence row 333 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. PubMed 40250991
Claim or source metadata contains an explicit term marker.
Evidence row 335 / safety context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol: a scoping review and commentary. PubMed 36710464
Claim or source metadata contains an explicit term marker.
Evidence row 336 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The potential role of cannabinoids in dermatology. PubMed 31599175
Claim or source metadata contains an explicit term marker.
Evidence row 337 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and the skin. PubMed 34785006
Claim or source metadata contains an explicit term marker.
Evidence row 339 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and Their Receptors in Skin Diseases. PubMed 38003712
Claim or source metadata contains an explicit term marker.
Evidence row 340 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. PubMed 41008526
Claim or source metadata contains an explicit term marker.
Evidence row 341 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. PubMed 33851375
Claim or source metadata contains an explicit term marker.
Evidence row 342 / safety context
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. PubMed 38904694
Claim or source metadata contains an explicit term marker.
Evidence row 343 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. PubMed 33909195
Claim or source metadata contains an explicit term marker.
Evidence row 344 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. PubMed 30138623
Claim or source metadata contains an explicit term marker.
Evidence row 345 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. PubMed 36439142
Claim or source metadata contains an explicit term marker.
Evidence row 346 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. PubMed 19608284
Claim or source metadata contains an explicit term marker.
Evidence row 348 / safety context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Claim or source metadata contains an explicit term marker.
Evidence row 349 / safety context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. PubMed 38686923
Claim or source metadata contains an explicit term marker.
Evidence row 352 / safety context
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. PubMed 36342930
Claim or source metadata contains an explicit term marker.
Evidence row 355 / safety context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. PubMed 37934167
Claim or source metadata contains an explicit term marker.
Evidence row 374 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The Psychiatric Consequences of Cannabinoids. PubMed 29678279
Claim or source metadata contains an explicit term marker.
Evidence row 375 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis dependence. PubMed 30687936
Claim or source metadata contains an explicit term marker.
Evidence row 376 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PubMed 32271390
Claim or source metadata contains an explicit term marker.
Evidence row 380 / safety context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. PubMed 36206805
Claim or source metadata contains an explicit term marker.
Evidence row 411 / safety context
CBD studied for Sleep.
insufficient / very_low confidence.
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. PubMed 41856154
Claim or source metadata contains an explicit term marker.
Evidence row 418 / safety context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. PubMed 38427284
Claim or source metadata contains an explicit term marker.
Evidence row 424 / safety context
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. PubMed 40072476
Claim or source metadata contains an explicit term marker.
Evidence row 513 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. PubMed 38924151
Claim or source metadata contains an explicit term marker.
Evidence row 514 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. PubMed 27428345
Claim or source metadata contains an explicit term marker.
Evidence row 515 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. PubMed 32053725
Claim or source metadata contains an explicit term marker.
Evidence row 516 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PubMed 36228902
Claim or source metadata contains an explicit term marker.
Evidence row 541 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Claim or source metadata contains an explicit term marker.
Evidence row 543 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Claim or source metadata contains an explicit term marker.
Evidence row 545 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Claim or source metadata contains an explicit term marker.
Evidence row 549 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. PubMed 39699828
Claim or source metadata contains an explicit term marker.
Evidence row 551 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Non-psychotropic cannabinoids as inhibitors of TET1 protein. PubMed 35462234
Claim or source metadata contains an explicit term marker.
Evidence row 552 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. PubMed 40326034
Claim or source metadata contains an explicit term marker.
Evidence row 553 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. PubMed 33562819
Claim or source metadata contains an explicit term marker.
Evidence row 555 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Claim or source metadata contains an explicit term marker.
Evidence row 557 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. PubMed 36497400
Claim or source metadata contains an explicit term marker.
Evidence row 558 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Claim or source metadata contains an explicit term marker.
Evidence row 559 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Claim or source metadata contains an explicit term marker.
Evidence row 638 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Claim or source metadata contains an explicit term marker.
Evidence row 639 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 640 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 642 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Claim or source metadata contains an explicit term marker.
Evidence row 645 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Claim or source metadata contains an explicit term marker.
Evidence row 647 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Claim or source metadata contains an explicit term marker.
Evidence row 648 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Claim or source metadata contains an explicit term marker.
Evidence row 649 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Claim or source metadata contains an explicit term marker.
Evidence row 650 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. PubMed 34622654
Claim or source metadata contains an explicit term marker.
Evidence row 652 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. PubMed 37396845
Claim or source metadata contains an explicit term marker.
Evidence row 653 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. PubMed 39172143
Claim or source metadata contains an explicit term marker.
Evidence row 656 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. PubMed 36854205
Claim or source metadata contains an explicit term marker.
Evidence row 736 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. PubMed 40270953
Claim or source metadata contains an explicit term marker.
Evidence row 737 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Claim or source metadata contains an explicit term marker.
Evidence row 739 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). PubMed 21740450
Claim or source metadata contains an explicit term marker.
Evidence row 741 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PubMed 38862388
Claim or source metadata contains an explicit term marker.
Evidence row 742 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 743 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 748 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. PubMed 37697897
Claim or source metadata contains an explicit term marker.
Evidence row 749 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. PubMed 35799289
Claim or source metadata contains an explicit term marker.
Evidence row 750 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PubMed 25542687
Claim or source metadata contains an explicit term marker.
Evidence row 753 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. PubMed 40131178
Claim or source metadata contains an explicit term marker.
Evidence row 754 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. PubMed 35303507
Claim or source metadata contains an explicit term marker.
Evidence row 756 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. PubMed 31549358
Claim or source metadata contains an explicit term marker.
Evidence row 757 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. PubMed 36280497
Claim or source metadata contains an explicit term marker.
Evidence row 758 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. PubMed 35585089
Claim or source metadata contains an explicit term marker.
Evidence row 759 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PubMed 23894589
Claim or source metadata contains an explicit term marker.
Evidence row 1063 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. PubMed 36150527
Claim or source metadata contains an explicit term marker.
Evidence row 1064 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Metabolism of endocannabinoids. PubMed 27516570
Claim or source metadata contains an explicit term marker.
Evidence row 1065 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide uptake explained? PubMed 22297258
Claim or source metadata contains an explicit term marker.
Evidence row 1066 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide receptors. PubMed 12052051
Claim or source metadata contains an explicit term marker.
Evidence row 1068 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid metabolism by cytochrome P450 monooxygenases. PubMed 25461979
Claim or source metadata contains an explicit term marker.
Evidence row 1069 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and pregnancy. PubMed 20302856
Claim or source metadata contains an explicit term marker.
Evidence row 1070 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Anandamide and its metabolites: what are their roles in the kidney? PubMed 27100705
Claim or source metadata contains an explicit term marker.
Evidence row 1074 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. PubMed 32867595
Claim or source metadata contains an explicit term marker.
Evidence row 1075 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Druggable Targets in Endocannabinoid Signaling. PubMed 32894511
Claim or source metadata contains an explicit term marker.
Evidence row 1076 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Chemical probes of endocannabinoid metabolism. PubMed 23512546
Claim or source metadata contains an explicit term marker.
Evidence row 1077 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Amygdala FAAH and anandamide: mediating protection and recovery from stress. PubMed 24325918
Claim or source metadata contains an explicit term marker.
Evidence row 1078 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The Endocannabinoid System and its Modulation by Phytocannabinoids. PubMed 26271952
Claim or source metadata contains an explicit term marker.
Evidence row 1079 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. PubMed 21418147
Claim or source metadata contains an explicit term marker.
Evidence row 1080 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabinergic ligands. PubMed 12505686
Claim or source metadata contains an explicit term marker.
Evidence row 1081 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. PubMed 16678907
Claim or source metadata contains an explicit term marker.
Evidence row 1082 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid overload. PubMed 20952498
Claim or source metadata contains an explicit term marker.
Evidence row 1083 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid hydrolases. PubMed 12432941
Claim or source metadata contains an explicit term marker.
Evidence row 1086 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. PubMed 36966972
Claim or source metadata contains an explicit term marker.
Evidence row 1090 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. PubMed 24676249
Claim or source metadata contains an explicit term marker.
Evidence row 1092 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and nutrition. PubMed 18426507
Claim or source metadata contains an explicit term marker.
Evidence row 1093 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
N-acylethanolamines, anandamide and food intake. PubMed 19413995
Claim or source metadata contains an explicit term marker.
Evidence row 1094 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. PubMed 19285259
Claim or source metadata contains an explicit term marker.
Evidence row 1095 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. PubMed 30537148
Claim or source metadata contains an explicit term marker.
Evidence row 1096 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
A fatty gut feeling. PubMed 23567058
Claim or source metadata contains an explicit term marker.
Evidence row 1098 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Regulation of food intake by oleoylethanolamide. PubMed 15770421
Claim or source metadata contains an explicit term marker.
Evidence row 1099 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? PubMed 40274041
Claim or source metadata contains an explicit term marker.
Evidence row 1100 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Brain molecules and appetite: the case of oleoylethanolamide. PubMed 23464987
Claim or source metadata contains an explicit term marker.
Evidence row 1104 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. PubMed 42068417
Claim or source metadata contains an explicit term marker.
Evidence row 1105 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. PubMed 31132422
Claim or source metadata contains an explicit term marker.
Evidence row 1107 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. PubMed 39714723
Claim or source metadata contains an explicit term marker.
Evidence row 1108 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
The search for the palmitoylethanolamide receptor. PubMed 15963531
Claim or source metadata contains an explicit term marker.
Evidence row 1111 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. PubMed 28215162
Claim or source metadata contains an explicit term marker.
Evidence row 1112 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabimimetic fatty acid derivatives in cancer and inflammation. PubMed 10785541
Claim or source metadata contains an explicit term marker.
Evidence row 1114 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. PubMed 33919499
Claim or source metadata contains an explicit term marker.
Evidence row 1115 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). PubMed 24602801
Claim or source metadata contains an explicit term marker.
Evidence row 1116 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. PubMed 22697514
Claim or source metadata contains an explicit term marker.
Evidence row 1119 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoid hydrolases. PubMed 12432941
Claim or source metadata contains an explicit term marker.
Evidence row 1120 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. PubMed 11945157
Claim or source metadata contains an explicit term marker.
Evidence row 1121 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: a member of the endocannabinoid family? PubMed 14691053
Claim or source metadata contains an explicit term marker.
Evidence row 1122 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? PubMed 17445087
Claim or source metadata contains an explicit term marker.
Evidence row 1123 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? PubMed 10469890
Claim or source metadata contains an explicit term marker.
Evidence row 1124 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The role of the CB1 receptor in the regulation of sleep. PubMed 18514375
Claim or source metadata contains an explicit term marker.
Evidence row 1126 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
The enzymatic inactivation of the fatty acid amide class of signaling lipids. PubMed 12505696
Claim or source metadata contains an explicit term marker.
Evidence row 1127 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. PubMed 10197045
Claim or source metadata contains an explicit term marker.
Evidence row 1131 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. PubMed 29082315
Claim or source metadata contains an explicit term marker.
Evidence row 1144 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and Their Pharmacological Actions. PubMed 26408156
Claim or source metadata contains an explicit term marker.
Evidence row 1146 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The cannabinoid receptors. PubMed 12432948
Claim or source metadata contains an explicit term marker.
Evidence row 1156 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Endocannabinoids and Their Pharmacological Actions. PubMed 26408156
Claim or source metadata contains an explicit term marker.
Evidence row 1157 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
GPR55: a new member of the cannabinoid receptor clan? PubMed 17876300
Claim or source metadata contains an explicit term marker.
Evidence row 1158 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
The role of the CB1 receptor in the regulation of sleep. PubMed 18514375
Claim or source metadata contains an explicit term marker.
Evidence row 1167 / safety context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. PubMed 22959887
Claim or source metadata contains an explicit term marker.
Evidence row 1171 / safety context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. PubMed 21810478
Claim or source metadata contains an explicit term marker.
Evidence row 1172 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Classical endocannabinoid-like compounds and their regulation by nutrients. PubMed 24677570
Claim or source metadata contains an explicit term marker.
Evidence row 1174 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. PubMed 24681513
Claim or source metadata contains an explicit term marker.
Evidence row 1180 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. PubMed 30070030
Claim or source metadata contains an explicit term marker.
Evidence row 1181 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. PubMed 11463796
Claim or source metadata contains an explicit term marker.
Evidence row 1186 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. PubMed 20353771
Claim or source metadata contains an explicit term marker.
Evidence row 1188 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. PubMed 24874648
Claim or source metadata contains an explicit term marker.
Evidence row 1195 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. PubMed 26839710
Claim or source metadata contains an explicit term marker.
Evidence row 1197 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. PubMed 23813098
Claim or source metadata contains an explicit term marker.
Evidence row 1202 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
insufficient / very_low confidence.
Cannabinoids and Sleep/Wake Control. PubMed 33537938
Claim or source metadata contains an explicit term marker.
Evidence Group
Preclinical
27 exact rows / 23 sources
Evidence row 89 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
preclinical / very_low confidence.
Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. PubMed 39200508
Claim or source metadata contains an explicit term marker.
Evidence row 110 / safety context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. PubMed 35364618
Claim or source metadata contains an explicit term marker.
Evidence row 116 / safety context
CBDV studied for Seizure and neurodevelopmental outcomes.
preclinical / very_low confidence.
Preclinical safety and efficacy of cannabidivarin for early life seizures. PubMed 30633929
Claim or source metadata contains an explicit term marker.
Evidence row 132 / safety context
CBDA studied for nausea-related or inflammation-related outcomes.
preclinical / very_low confidence.
Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. PubMed 26439367
Claim or source metadata contains an explicit term marker.
Evidence row 171 / safety context
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Claim or source metadata contains an explicit term marker.
Evidence row 172 / safety context
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 174 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 223 / safety context
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PubMed 36603937
Claim or source metadata contains an explicit term marker.
Evidence row 353 / safety context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PubMed 40643195
Claim or source metadata contains an explicit term marker.
Evidence row 356 / safety context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. PubMed 40176500
Claim or source metadata contains an explicit term marker.
Evidence row 550 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. PubMed 40523564
Claim or source metadata contains an explicit term marker.
Evidence row 643 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Claim or source metadata contains an explicit term marker.
Evidence row 644 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 646 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 744 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 747 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. PubMed 42151379
Claim or source metadata contains an explicit term marker.
Evidence row 1091 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. PubMed 38052772
Claim or source metadata contains an explicit term marker.
Evidence row 1154 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. PubMed 15763177
Claim or source metadata contains an explicit term marker.
Evidence row 1176 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. PubMed 36733808
Claim or source metadata contains an explicit term marker.
Evidence row 1178 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. PubMed 18316044
Claim or source metadata contains an explicit term marker.
Evidence row 1182 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. PubMed 36316276
Claim or source metadata contains an explicit term marker.
Evidence row 1187 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. PubMed 31881191
Claim or source metadata contains an explicit term marker.
Evidence row 1194 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats. PubMed 38279735
Claim or source metadata contains an explicit term marker.
Evidence row 1196 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Effects of N-stearoylethanolamine on the emotionality and learning ability of rats]. PubMed 25566671
Claim or source metadata contains an explicit term marker.
Evidence row 1198 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Immunosuppressive characteristics of N-stearoylethanolamine a stable compound with cannabimimetic activity]. PubMed 18710028
Claim or source metadata contains an explicit term marker.
Evidence row 1199 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
[Anti-inflammatory effect of N-stearoylethanolamine in experimental burn injury in rats]. PubMed 19873884
Claim or source metadata contains an explicit term marker.
Evidence row 1201 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
preclinical / very_low confidence.
Exploring the Utility of Hair Endocannabinoids for Monitoring Homeostasis in Bonobos. PubMed 33434116
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
98 exact rows / 93 sources
Evidence row 44 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
mechanistic or pharmacological / very_low confidence.
Cannabis Therapeutics and the Future of Neurology. PubMed 30405366
Claim or source metadata contains an explicit term marker.
Evidence row 47 / safety context
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
mechanistic or pharmacological / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 77 / safety context
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Claim or source metadata contains an explicit term marker.
Evidence row 88 / safety context
THCA studied for THCA-specific safety, effect, or mechanism claims.
mechanistic or pharmacological / very_low confidence.
Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. PubMed 41358942
Claim or source metadata contains an explicit term marker.
Evidence row 157 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 161 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Claim or source metadata contains an explicit term marker.
Evidence row 164 / safety context
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Claim or source metadata contains an explicit term marker.
Evidence row 165 / safety context
CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PubMed 41822224
Claim or source metadata contains an explicit term marker.
Evidence row 243 / safety context
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PubMed 42106886
Claim or source metadata contains an explicit term marker.
Evidence row 322 / safety context
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoid treatment for autism: a proof-of-concept randomized trial. PubMed 33536055
Claim or source metadata contains an explicit term marker.
Evidence row 347 / safety context
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. PubMed 31350927
Claim or source metadata contains an explicit term marker.
Evidence row 422 / safety context
CBD studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. PubMed 29540584
Claim or source metadata contains an explicit term marker.
Evidence row 511 / safety context
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Claim or source metadata contains an explicit term marker.
Evidence row 542 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 547 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. PubMed 36796712
Claim or source metadata contains an explicit term marker.
Evidence row 548 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PubMed 40540228
Claim or source metadata contains an explicit term marker.
Evidence row 554 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. PubMed 41548647
Claim or source metadata contains an explicit term marker.
Evidence row 556 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The impact of cannabigerol exposure on human endometrial stromal cells decidualization. PubMed 42107483
Claim or source metadata contains an explicit term marker.
Evidence row 560 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. PubMed 36272108
Claim or source metadata contains an explicit term marker.
Evidence row 561 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. PubMed 41934896
Claim or source metadata contains an explicit term marker.
Evidence row 562 / safety context
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Claim or source metadata contains an explicit term marker.
Evidence row 606 / safety context
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 636 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Claim or source metadata contains an explicit term marker.
Evidence row 651 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. PubMed 33134364
Claim or source metadata contains an explicit term marker.
Evidence row 654 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. PubMed 20619971
Claim or source metadata contains an explicit term marker.
Evidence row 655 / safety context
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. PubMed 41668212
Claim or source metadata contains an explicit term marker.
Evidence row 738 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Claim or source metadata contains an explicit term marker.
Evidence row 740 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. PubMed 42196303
Claim or source metadata contains an explicit term marker.
Evidence row 746 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. PubMed 41947574
Claim or source metadata contains an explicit term marker.
Evidence row 751 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Evidence row 752 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hair Regrowth with Novel Hemp Extract: A Case Series. PubMed 37305187
Claim or source metadata contains an explicit term marker.
Evidence row 755 / safety context
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. PubMed 23712280
Claim or source metadata contains an explicit term marker.
Evidence row 1023 / safety context
Endocannabinoids modulates TRPV4.
mechanistic or pharmacological / very_low confidence.
Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. PubMed 38750093
Claim or source metadata contains an explicit term marker.
Evidence row 1067 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells. PubMed 34126378
Claim or source metadata contains an explicit term marker.
Evidence row 1071 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endocannabinoids. PubMed 35038882
Claim or source metadata contains an explicit term marker.
Evidence row 1072 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid CB1 receptors regulate salivation. PubMed 35986066
Claim or source metadata contains an explicit term marker.
Evidence row 1073 / safety context
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. PubMed 11470906
Claim or source metadata contains an explicit term marker.
Evidence row 1084 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. PubMed 39612328
Claim or source metadata contains an explicit term marker.
Evidence row 1085 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. PubMed 24768821
Claim or source metadata contains an explicit term marker.
Evidence row 1087 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. PubMed 36125319
Claim or source metadata contains an explicit term marker.
Evidence row 1088 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. PubMed 33450278
Claim or source metadata contains an explicit term marker.
Evidence row 1089 / safety context
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. PubMed 36481187
Claim or source metadata contains an explicit term marker.
Evidence row 1097 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. PubMed 17449181
Claim or source metadata contains an explicit term marker.
Evidence row 1101 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. PubMed 29936173
Claim or source metadata contains an explicit term marker.
Evidence row 1102 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
GPR119 Is a Potent Regulator of Human Sebocyte Biology. PubMed 32142797
Claim or source metadata contains an explicit term marker.
Evidence row 1103 / safety context
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. PubMed 30702457
Claim or source metadata contains an explicit term marker.
Evidence row 1106 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. PubMed 35176443
Claim or source metadata contains an explicit term marker.
Evidence row 1109 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. PubMed 40563990
Claim or source metadata contains an explicit term marker.
Evidence row 1110 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. PubMed 41709243
Claim or source metadata contains an explicit term marker.
Evidence row 1113 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Protective effect of palmitoylethanolamide in a rat model of cystitis. PubMed 25463999
Claim or source metadata contains an explicit term marker.
Evidence row 1117 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. PubMed 27720681
Claim or source metadata contains an explicit term marker.
Evidence row 1118 / safety context
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. PubMed 28336953
Claim or source metadata contains an explicit term marker.
Evidence row 1125 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. PubMed 9344854
Claim or source metadata contains an explicit term marker.
Evidence row 1128 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. PubMed 10221757
Claim or source metadata contains an explicit term marker.
Evidence row 1129 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. PubMed 8900284
Claim or source metadata contains an explicit term marker.
Evidence row 1130 / safety context
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. PubMed 10574567
Claim or source metadata contains an explicit term marker.
Evidence row 1132 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. PubMed 15245490
Claim or source metadata contains an explicit term marker.
Evidence row 1133 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. PubMed 17459108
Claim or source metadata contains an explicit term marker.
Evidence row 1134 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. PubMed 24644287
Claim or source metadata contains an explicit term marker.
Evidence row 1135 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endovanilloids are potential activators of the trigeminovascular nocisensor complex. PubMed 27189587
Claim or source metadata contains an explicit term marker.
Evidence row 1136 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. PubMed 20354008
Claim or source metadata contains an explicit term marker.
Evidence row 1137 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. PubMed 15289293
Claim or source metadata contains an explicit term marker.
Evidence row 1138 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. PubMed 15006899
Claim or source metadata contains an explicit term marker.
Evidence row 1139 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. PubMed 25995819
Claim or source metadata contains an explicit term marker.
Evidence row 1140 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. PubMed 28701511
Claim or source metadata contains an explicit term marker.
Evidence row 1141 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. PubMed 16760924
Claim or source metadata contains an explicit term marker.
Evidence row 1142 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. PubMed 33568652
Claim or source metadata contains an explicit term marker.
Evidence row 1143 / safety context
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. PubMed 17984664
Claim or source metadata contains an explicit term marker.
Evidence row 1145 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. PubMed 11259648
Claim or source metadata contains an explicit term marker.
Evidence row 1147 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. PubMed 17698254
Claim or source metadata contains an explicit term marker.
Evidence row 1148 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. PubMed 16639008
Claim or source metadata contains an explicit term marker.
Evidence row 1149 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. PubMed 12787057
Claim or source metadata contains an explicit term marker.
Evidence row 1150 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. PubMed 15901805
Claim or source metadata contains an explicit term marker.
Evidence row 1151 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model. PubMed 37085778
Claim or source metadata contains an explicit term marker.
Evidence row 1152 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. PubMed 15148262
Claim or source metadata contains an explicit term marker.
Evidence row 1153 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. PubMed 22309979
Claim or source metadata contains an explicit term marker.
Evidence row 1155 / safety context
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. PubMed 12356827
Claim or source metadata contains an explicit term marker.
Evidence row 1159 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. PubMed 18806815
Claim or source metadata contains an explicit term marker.
Evidence row 1160 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. PubMed 12023533
Claim or source metadata contains an explicit term marker.
Evidence row 1161 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. PubMed 22454039
Claim or source metadata contains an explicit term marker.
Evidence row 1162 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. PubMed 32696508
Claim or source metadata contains an explicit term marker.
Evidence row 1163 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. PubMed 15233865
Claim or source metadata contains an explicit term marker.
Evidence row 1164 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. PubMed 29958841
Claim or source metadata contains an explicit term marker.
Evidence row 1165 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Mechanism of platelet activation induced by endocannabinoids in blood and plasma. PubMed 23789792
Claim or source metadata contains an explicit term marker.
Evidence row 1166 / safety context
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. PubMed 19255745
Claim or source metadata contains an explicit term marker.
Evidence row 1168 / safety context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. PubMed 27809877
Claim or source metadata contains an explicit term marker.
Evidence row 1169 / safety context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. PubMed 23570577
Claim or source metadata contains an explicit term marker.
Evidence row 1170 / safety context
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. PubMed 27759003
Claim or source metadata contains an explicit term marker.
Evidence row 1177 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. PubMed 35203453
Claim or source metadata contains an explicit term marker.
Evidence row 1179 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine. PubMed 21573043
Claim or source metadata contains an explicit term marker.
Evidence row 1183 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. PubMed 26707833
Claim or source metadata contains an explicit term marker.
Evidence row 1184 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. PubMed 16081411
Claim or source metadata contains an explicit term marker.
Evidence row 1185 / safety context
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. PubMed 17574742
Claim or source metadata contains an explicit term marker.
Evidence row 1189 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. PubMed 12010121
Claim or source metadata contains an explicit term marker.
Evidence row 1190 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PubMed 22125609
Claim or source metadata contains an explicit term marker.
Evidence row 1191 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. PubMed 23707281
Claim or source metadata contains an explicit term marker.
Evidence row 1193 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. PubMed 27531672
Claim or source metadata contains an explicit term marker.
Evidence row 1200 / safety context
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. PubMed 16154384
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
outcome
Adverse events
109 evidence rows / 74 sources
outcome
Side effect frequency
7 evidence rows / 4 sources
safety
Pregnancy and pediatrics
129 evidence rows / 106 sources
safety
Sedation and somnolence
81 evidence rows / 53 sources
safety
Drug interactions
35 evidence rows / 22 sources
safety
Psychiatric risk
17 evidence rows / 16 sources
safety
Liver enzymes and hepatotoxicity
17 evidence rows / 15 sources
safety
Cardiovascular risk
16 evidence rows / 14 sources
Nearby Terms